Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid Abstract #2891

Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Aim(s): To evaluate SREs and their outcomes in NEN pts with BM, treated with zoledronic acid (ZA).
Materials and methods: The diagnosis of NEN BM was based on molecular and/or cross-sectional imaging. Eligible pts received at least 2 cycles of ZA and time to first SRE was defined as presence of a pathological fracture, and/or need for spinal surgery and/or external beam radiotherapy (EBR) for pain control or spinal cord compression. Time to SRE and overall survival (OS) were estimated using the Kaplan-Meier method.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1912 Skeletal-Related Events (SREs) and Use of Antiresorptive Therapy (ART) in Patients with Bone Metastases of Neuroendocrine Neoplasms
Introduction: Antiresorptive therapy (ART) with bisphosphonates or denosumab is effective in preventing skeletal-related events (SREs) in patients with bone metastases (BM). In neuroendocrine neoplasms (NEN), BM are a negative prognostic factor, however tend to be asymptomatic and SREs are considered rare. The role of ART in preventing SREs in NEN has not been investigated so far.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Others
Presenting Author: Dr. med. Leonidas Apostolidis
#2791 NEN Skeletal Metastasis Performance and the Correlation with Cell Proliferation: 112 Cases of 68Ga-DOTA-TATE Results Analysis
Introduction: 68Ga-DOTA-TATE PET/CT plays an important role in neuroendocrine neoplasm(NEN)diagnosis and biological charecteristcs evaluation.Skeleton is the second common metastatic organ in NEN after liver and it affects the quality of patient’s life.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Jiangyuan Yu
Authors: Xie Q, Lu M, Li J, Li N, ...
#2889 Transcatheter Arterial Embolization (TAE) of NEN Metastases: Efficacy and Predictors of Response
Introduction: Transcatheter-Arterial embolization (TAE) is an established regional, palliative treatment option for liver metastases in patients (pts) with neuroendocrine neoplasms (NENs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Eleni Armeni
#2903 Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. A Single-Institution Experience
Introduction: The incidence of BM in NET is underestimated and there is no consensus on clinical features, diagnostic techniques, and treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Valeria Smiroldo
Authors: Smiroldo V, Lania A, Pedicini V, Pepe G, ...
#1271 Bone Metastases in NEN Patients - Frequency, Clinical, Therapeutic and Prognostic Relevance
Introduction: Up to 73% of patients with neuroendocrine neoplasms (NEN) present with distant metastases at diagnosis. Advanced stage negatively correlates with prognosis. Bone metastases (BM) are usually reported in less than 10% of patients. Improved imaging results in more frequent detection but information in general is very limited.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Michael Scharf
Authors: Scharf M, Michel V, Rinke A, Gress T, ...